Effect of Trilaciclib on Myelosuppression in Previously Treated ExtensiveStage SmallCell Lung Cancer

Effect of Trilaciclib on Myelosuppression in Previously Treated Extensive-Stage Small-Cell Lung Cancer

Researchers evaluated the effect of trilaciclib to a topotecan regimen in reducing chemotherapy-induced myelosuppression in newly diagnosed extensive-stage small-cell lung cancer.

More From BioPortfolio on "Effect of Trilaciclib on Myelosuppression in Previously Treated Extensive-Stage Small-Cell Lung Cancer"